Technical Analysis for MEIP - MEI Pharma, Inc.

Grade Last Price % Change Price Change
grade C 2.0 0.50% 0.01
MEIP closed up 0.5 percent on Wednesday, September 18, 2019, on 86 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical MEIP trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Walk Strength 0.50%
Wide Bands Range Expansion 0.50%
Overbought Stochastic Strength 0.50%
Upper Bollinger Band Touch Strength 0.50%
Shooting Star Candlestick Bearish 0.25%
New Uptrend Bullish 0.25%

Older signals for MEIP ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
MEI Pharma, Inc., a development stage oncology company, focuses on the clinical development of therapeutics for the treatment of cancer. It develops various lead drug candidates, including ME-143 that has completed Phase I clinical trials in patients with refractory solid tumors; ME-344, an active metabolite of NV-128, which is in Phase I clinical trials in patients with solid refractory tumors; and Pracinostat, an orally histone deacetylase inhibitor that has completed various Phase I clinical trials in patients with hematologic disorders. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a subsidiary of Novogen Limited. MEI Pharma, Inc. (NasdaqCM:MEIP) operates independently of Novogen Limited as of December 03, 2012.
Medicine Cancer Clinical Medicine Treatment Of Cancer Virotherapy Seattle Genetics Kite Pharma Hematologic Disorders Refractory Solid Tumors
Is MEIP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.61
52 Week Low 1.44
Average Volume 306,619
200-Day Moving Average 2.5477
50-Day Moving Average 1.7631
20-Day Moving Average 1.7793
10-Day Moving Average 1.8905
Average True Range 0.118
ADX 25.95
+DI 23.0061
-DI 13.1939
Chandelier Exit (Long, 3 ATRs ) 1.716
Chandelier Exit (Short, 3 ATRs ) 1.854
Upper Bollinger Band 2.0699
Lower Bollinger Band 1.4887
Percent B (%b) 0.88
BandWidth 32.664531
MACD Line 0.0672
MACD Signal Line 0.0272
MACD Histogram 0.04
Fundamentals Value
Market Cap 73.88 Million
Num Shares 36.9 Million
EPS 0.07
Price-to-Earnings (P/E) Ratio 28.57
Price-to-Sales 4.35
Price-to-Book 1.98
PEG Ratio 23.80
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.18
Resistance 3 (R3) 2.17 2.09 2.15
Resistance 2 (R2) 2.09 2.05 2.10 2.14
Resistance 1 (R1) 2.05 2.02 2.06 2.06 2.13
Pivot Point 1.97 1.97 1.98 1.98 1.97
Support 1 (S1) 1.93 1.93 1.94 1.94 1.87
Support 2 (S2) 1.85 1.90 1.86 1.86
Support 3 (S3) 1.81 1.85 1.85
Support 4 (S4) 1.82